Fed­er­al cir­cuit up­holds Te­va-Glax­o­SmithK­line de­ci­sion, land­ing an­oth­er blow to 'skin­ny' la­bels

Nor­mal­ly, new gener­ic drug com­pe­ti­tion can en­ter the mar­ket for one or some of the ap­proved in­di­ca­tions of its brand-name coun­ter­part’s la­bel. That new gener­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.